Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Thursday

Aprea Therapeutics (NASDAQ:APRE) is expected to be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Aprea Therapeutics to post earnings of ($0.11) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.24. The firm had revenue of $0.12 million for the quarter. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative return on equity of 78.90%. On average, analysts expect Aprea Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Up 2.1%

Shares of APRE stock opened at $1.45 on Thursday. Aprea Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $5.00. The firm’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.64. The stock has a market cap of $8.45 million, a price-to-earnings ratio of -0.62 and a beta of 1.30.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $15.50.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.